These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34927371)

  • 1. Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.
    Yang Y; Zhang T; Zhou Z; Liang J; Chen D; Feng Q; Xiao Z; Hui Z; Lv J; Deng L; Wang X; Wang W; Wang J; Liu W; Zhai Y; Wang J; Bi N; Wang L
    Thorac Cancer; 2022 Feb; 13(3):296-307. PubMed ID: 34927371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.
    Duijm M; Oomen-de Hoop E; van Voort van der Zyp N; van de Vaart P; Tekatli H; Hoogeman M; Senan S; Nuyttens J
    Radiother Oncol; 2021 Mar; 156():223-230. PubMed ID: 33418006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort.
    Zuo Z; Zhang G; Song P; Yang J; Li S; Zhong Z; Tan Q; Wang L; Xue Q; Gao S; Sun N; He J
    Ann Surg Oncol; 2021 Jul; 28(7):3941-3950. PubMed ID: 33249521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer.
    Liang W; Zhang L; Jiang G; Wang Q; Liu L; Liu D; Wang Z; Zhu Z; Deng Q; Xiong X; Shao W; Shi X; He J
    J Clin Oncol; 2015 Mar; 33(8):861-9. PubMed ID: 25624438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
    Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer.
    Baker S; Bakunina K; Duijm M; Hoogeman MS; Cornelissen R; Antonisse I; Praag J; Heemsbergen WD; Nuyttens JJ
    Radiat Oncol; 2020 Apr; 15(1):89. PubMed ID: 32321553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy].
    Li F; Bai H; Li X; Wu M; Yu R; Shi A; Yin L; Wang J; Zhu G
    Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):715-8. PubMed ID: 21924037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiomics Nomogram for Predicting Locoregional Failure in Locally Advanced Non-small Cell Lung Cancer Treated with Definitive Chemoradiotherapy.
    Chen X; Tong X; Qiu Q; Sun F; Yin Y; Gong G; Xing L; Sun X
    Acad Radiol; 2022 Feb; 29 Suppl 2():S53-S61. PubMed ID: 33308945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of nomograms for predicting survival of elderly patients with stage I small-cell lung cancer.
    Yang Y; Sun S; Wang Y; Xiong F; Xiao Y; Huang J
    Bosn J Basic Med Sci; 2021 Oct; 21(5):632-641. PubMed ID: 33577444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
    Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
    Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting severe acute radiation pneumonitis in patients with non-small cell lung cancer receiving postoperative radiotherapy: Development and internal validation of a nomogram based on the clinical and dose-volume histogram parameters.
    Tang X; Li Y; Tian X; Zhou X; Wang Y; Huang M; Ren L; Zhou L; Xue J; Ding Z; Zhu J; Xu Y; Peng F; Wang J; Lu Y; Gong Y
    Radiother Oncol; 2019 Mar; 132():197-203. PubMed ID: 30385172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC).
    Zhu X; Hou R; Li X; Jiang C; Xia W; Fu X
    Radiat Oncol; 2020 Feb; 15(1):43. PubMed ID: 32070383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.
    Xie D; Allen MS; Marks R; Jiang G; Sun Z; Nichols F; Zhang M; Chen C; Aubry MC; Jatoi A; Garces YI; Mansfield A; Wigle D; Molina J; Deschamps C; Yang P
    Eur J Cardiothorac Surg; 2018 Jun; 53(6):1214-1222. PubMed ID: 29293957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Validation of Nomogram Model Integrated With Inflammation-Based Factors for the Prognosis of Advanced Non-Small Cell Lung Cancer.
    Huang Z; Xing S; Zhu Y; Qu Y; Jiang L; Sheng J; Wang Q; Xu S; Xue N
    Technol Cancer Res Treat; 2020; 19():1533033820971605. PubMed ID: 33191854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of prognostic nomogram for T
    Mei W; Yao W; Song Z; Jiao W; Zhu L; Huang Q; An C; Shi J; Yu G; Sun P; Zhang Y; Shen J; Xu C; Yang H; Wang Q; Zhu Z
    BMC Cancer; 2023 Jul; 23(1):715. PubMed ID: 37525124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients.
    Wu J; Zhou L; Huang L; Gu J; Li S; Liu B; Feng J; Zhou Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):4. PubMed ID: 28057025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of surgery on survival in patients with stage III N2 small cell lung cancer: propensity score matching analysis and nomogram development and validation.
    Chai Y; Ma Y; Feng W; Lu H; Jin L
    World J Surg Oncol; 2021 Aug; 19(1):258. PubMed ID: 34461929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
    Sun XS; Li XY; Xiao BB; Liu SL; Chen QY; Tang LQ; Mai HQ
    Oral Oncol; 2020 Jan; 100():104490. PubMed ID: 31790913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.